We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

A new interdisciplinary study at the University of Delaware seeks to study AD by examining changes in the arteries and brain ...

From happy moments to heartbreak, our phones' photo reminders might be messing with how we remember—and forget.

Researchers map the unique genetic regulation of proteins in human cerebrospinal fluid, identifying potential targets for ...

Alzheimer’s Clinical Data: High exposure at three significant Alzheimer ... clearance in 2020 as a portable magnetic resonance brain imaging device for producing images that display the internal ...

Galantamine slowed decline in cognitive function, functional ability, and behavior at 6 months in people with Alzheimer's ...

That disease is Alzheimer’s disease. Let’s begin with some definitions. Alzheimer’s disease is a degenerative brain disease caused by complex brain changes following cell damage. Symptoms gradually ...

It seems like every day a new study emerges linking Ozempic and similar drugs to new health benefits. Ozempic is part of a drug class known as GLP-1 medications, which mimic gut hormones that help ...

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

The study expands on prior work (Piccirella et al, JPAD, 2022), positioning U-p53AZ as a robust tool for both early and advanced AD detection. Its potential for clinical application in diagnostic ...

Hyperfine, Inc. announced the presentation of additional research data and images using the Swoop® system to image patients ...